XASX
HPC
Market cap2mUSD
May 30, Last price
0.01AUD
1D
0.00%
1Q
0.00%
IPO
-96.72%
Name
Hydration Pharmaceuticals Co Ltd
Chart & Performance
P/E
0.93
P/S
0.78
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
36.27%
Rev. gr., 5y
1.58%
Revenues
3m
-68.08%
Net income
3m
P
CFO
-3m
L-47.30%
Profile
The Hydration Pharmaceuticals Company Limited markets and sells a range of liquid, tablet, and powder healthy hydration products in Australia, the Unites States, and Canada. It sells its products under the Hydralyte brand name through retail stores and e-commerce channels. The company was founded in 2001 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 3,205 -68.08% | 10,041 10.34% | 9,100 53.75% | ||||
Cost of revenue | 7,402 | 17,783 | 19,802 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (4,197) | (7,742) | (10,702) | ||||
NOPBT Margin | |||||||
Operating Taxes | (1) | 274 | |||||
Tax Rate | |||||||
NOPAT | (4,197) | (7,742) | (10,975) | ||||
Net income | 2,668 -132.92% | (8,102) -23.61% | (10,607) 18.30% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | (24) | 2,716 | |||||
BB yield | 0.50% | -57.99% | |||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | 3,893 | 3,712 | |||||
Deferred revenue | |||||||
Other long-term liabilities | 21 | 23 | 22 | ||||
Net debt | (3,217) | 2,052 | (976) | ||||
| Cash flow | |||||||
Cash from operating activities | (3,020) | (5,730) | (9,752) | ||||
CAPEX | |||||||
Cash from investing activities | 9,444 | ||||||
Cash from financing activities | (3,628) | 2,716 | 4,076 | ||||
FCF | (2,479) | (6,433) | (11,428) | ||||
| Balance | |||||||
Cash | 3,217 | 1,840 | 4,688 | ||||
Long term investments | |||||||
Excess cash | 3,056 | 1,338 | 4,233 | ||||
Stockholders' equity | 2,742 | (358) | 3,981 | ||||
Invested Capital | 21 | 3,916 | 3,734 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 266,753 | 195,129 | 162,680 | ||||
Price | 0.02 -25.00% | 0.02 -73.33% | 0.09 -70.00% | ||||
Market cap | 4,802 2.53% | 4,683 -68.01% | 14,641 -35.39% | ||||
EV | 1,585 | 6,736 | 13,665 | ||||
EBITDA | (4,197) | (7,742) | (10,702) | ||||
EV/EBITDA | |||||||
Interest | 1,764 | 643 | 91 | ||||
Interest/NOPBT | |||||||